Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (41-50 of 236) with videos related to

Pageof 24
Sort By:
Nature Medicine|May 8, 2010
Beta-catenin does not regulate memory T cell phenotypeGregory Driessens, Yan Zheng, Thomas F Gajewski
Immunological Reviews|May 12, 2009
Costimulatory and coinhibitory receptors in anti-tumor immunityGregory Driessens, Justin Kline, Thomas F Gajewski
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2006
Immune suppression in the tumor microenvironmentThomas F Gajewski, Yuru Meng, Helena Harlin
Blood|May 7, 2009
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia modelLong Zhang, Thomas F Gajewski, Justin Kline
Cancer Immunology, Immunotherapy : CII|December 16, 2004
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapyChristian Blank, Thomas F Gajewski, Andreas Mackensen
EMBO Reports|January 5, 2008
Molecular regulation of T-cell anergyYan Zheng, Yuanyuan Zha, Thomas F Gajewski
Journal for Immunotherapy of Cancer|April 19, 2019
Exploring the emerging role of the microbiome in cancer immunotherapyJessica Fessler, Vyara Matson, Thomas F Gajewski
Cell Research|April 27, 2016
MYC - a thorn in the side of cancer immunityStefani Spranger, Thomas F Gajewski, Justin Kline
Cancer Chemotherapy and Pharmacology|July 15, 2009
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanomaFrederick Locke, Joseph I Clark, Thomas F Gajewski
European Journal of Immunology|September 30, 2003
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xLMary A Markiewicz, Ian Brown, Thomas F Gajewski
Pageof 24

Showing results (41-50 of 236) with videos related to

Sort By:
Pageof 24
Nature Medicine|May 8, 2010
Beta-catenin does not regulate memory T cell phenotypeGregory Driessens, Yan Zheng, Thomas F Gajewski
Immunological Reviews|May 12, 2009
Costimulatory and coinhibitory receptors in anti-tumor immunityGregory Driessens, Justin Kline, Thomas F Gajewski
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2006
Immune suppression in the tumor microenvironmentThomas F Gajewski, Yuru Meng, Helena Harlin
Blood|May 7, 2009
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia modelLong Zhang, Thomas F Gajewski, Justin Kline
Cancer Immunology, Immunotherapy : CII|December 16, 2004
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapyChristian Blank, Thomas F Gajewski, Andreas Mackensen
EMBO Reports|January 5, 2008
Molecular regulation of T-cell anergyYan Zheng, Yuanyuan Zha, Thomas F Gajewski
Journal for Immunotherapy of Cancer|April 19, 2019
Exploring the emerging role of the microbiome in cancer immunotherapyJessica Fessler, Vyara Matson, Thomas F Gajewski
Cell Research|April 27, 2016
MYC - a thorn in the side of cancer immunityStefani Spranger, Thomas F Gajewski, Justin Kline
Cancer Chemotherapy and Pharmacology|July 15, 2009
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanomaFrederick Locke, Joseph I Clark, Thomas F Gajewski
European Journal of Immunology|September 30, 2003
Death of peripheral CD8+ T cells in the absence of MHC class I is Fas-dependent and not blocked by Bcl-xLMary A Markiewicz, Ian Brown, Thomas F Gajewski
Pageof 24